Acquisition by Van Der Baan Bastiaan Jeroen of 10000 shares of Lixte Biotechnology subject to Rule 16b-3

LIXT Stock  USD 1.95  0.11  5.98%   
Slightly above 72 percent of all Lixte Biotechnology's private investors are curious in acquiring. The analysis of the overall investor sentiment regarding Lixte Biotechnology Holdings suggests that a large number of traders are confidant. Lixte Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Lixte Biotechnology's earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by Lixte Biotechnology Holdi director. Grant, award or other acquisition pursuant to Rule 16b-3(d)

Read at macroaxis.com
Lixte insider trading alert for grant of options to purchase common stock by Van Der Baan Bastiaan Jeroen, the corporate stakeholder, on 7th of July 2023. This event was filed by Lixte Biotechnology Holdi with SEC on 2023-07-07. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Lixte Biotechnology's cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Lixte Biotechnology's relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Lixte Biotechnology Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Lixte Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Lixte Biotechnology Fundamental Analysis

We analyze Lixte Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lixte Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lixte Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Asset

Current Asset Comparative Analysis

Lixte Biotechnology is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.

Lixte Biotechnology Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Lixte Biotechnology stock to make a market-neutral strategy. Peer analysis of Lixte Biotechnology could also be used in its relative valuation, which is a method of valuing Lixte Biotechnology by comparing valuation metrics with similar companies.

Peers

Lixte Biotechnology Related Equities

PMVPPmv Pharmaceuticals   3.82   
0%
63.0%
OLMAOlema Pharmaceuticals   2.12   
0%
35.0%
KTTAPasithea Therapeutics   0.73   
0%
12.0%
SRRKScholar Rock   1.56   
25.0%
0%
ALLRAllarity Therapeutics   1.90   
31.0%
0%
INDPIndaptus Therapeutics   2.00   
33.0%
0%
VRAXVirax Biolabs   2.35   
38.0%
0%
NRBONeurobo Pharmaceuticals   2.59   
42.0%
0%
PASGPassage Bio   3.80   
62.0%
0%
BDRXBiodexa Pharmaceticals   4.91   
81.0%
0%
QNRXQuoin Pharmaceuticals   6.05   
100.0%
0%

Additional Tools for Lixte Stock Analysis

When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.